MDK-4204
| Code | Size | Price |
|---|
| TAR-T27998-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T27998-50mg | 50mg | £1,661.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T27998-100mg | 100mg | £2,079.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
MDK-4204, an anticancer agent, shows significant anti-cancer activity with IC50 values of 8.8 ?M and 9.5 ?M in PC-3 and DU-145 cells, respectively.
CAS:
1983924-20-4
Formula:
C31H29FN4O
Molecular Weight:
492.598
Purity:
0.98
SMILES:
Cc1ccc(C=C2/CN(Cc3cn(Cc4ccccc4F)nn3)CC(=C/c3ccc(C)cc3)C2=O)cc1
References
1. Miyake H, Imai S, Tamura K, Sugiyama T, Furuse H, Ozono S, Fujisawa M. Comparison of Tyrosine Kinase Inhibitor Versus Mammalian Target of Rapamycin Inhibitor as Second-line Molecular-targeted Therapy for Patients with Poor-risk Metastatic Renal Cell Carcinoma. Anticancer Res. 2017 Mar;37(3):1523-1528. PubMed PMID: 28314328.
2. Arvanitis CD, Bazan-Peregrino M, Rifai B, Seymour LW, Coussios CC. Cavitation-enhanced extravasation for drug delivery. Ultrasound Med Biol. 2011 Nov;37(11):1838-52. doi: 10.1016/j.ultrasmedbio.2011.08.004. Epub 2011 Oct 2. PubMed PMID: 21963037.
3. Beck R, Dejeans N, Glorieux C, Pedrosa RC, V?squez D, Valderrama JA, Calderon PB, Verrax J. Molecular chaperone Hsp90 as a target for oxidant-based anticancer therapies. Curr Med Chem. 2011;18(18):2816-25. Review. PubMed PMID: 21568884.
4. Ahn S, Kearbey JD, Li CM, Duke CB 3rd, Miller DD, Dalton JT. Biotransformation of a novel antimitotic agent, I-387, by mouse, rat, dog, monkey, and human liver microsomes and in vivo pharmacokinetics in mice. Drug Metab Dispos. 2011 Apr;39(4):636-43. doi: 10.1124/dmd.110.036673. Epub 2011 Jan 13. PubMed PMID: 21233217.